Voyager Shareholders Approve Merger With VERAXA Biotech, Expected To Go Public On Nasdaq Under 'VRXA' After Merger

Voyager Acquisition Corporation (NASDAQ: "VACHU," "VACH," "VACHW") ("Voyager" or the "Company") held the general meeting on March 12, 2026 and approved the previously announced business combination (the "Business Combination") with VERAXA Biotech AG ("VERAXA"). After the closing of the Business Combination, it is expected that the combined company will trade on Nasdaq under the new symbol ("VRXA"). As previously announced, holders of 25,217,315 of the Company's Class A ordinary shares ("Class A shares") exercised their right to redeem their shares for a pro rata portion of the funds in the Company's trust account, reflecting redemptions of approximately 99.67% of the total Class A shares outstanding in connection with the completion of the Business Combination pursuant to the business combination agreement between the Company, VERAXA and the other parties thereto (the "Business Combination Agreement"). The 25,217,315 Class A shares, which were submitted for redemption, have not been withdrawn and will accordingly be redeemed pursuant to the option to redeem provided to holders of the Company's Class A shares. As a result, assuming redemption elections are not withdrawn or reversed, following the effectuation of redemptions approximately $885,556 will remain in the Company's trust account and 82,685 Class A shares will convert into shares of the combined company, Veraxa Biotech Holding AG.

The closing of the Business Combination is subject to listing approvals by Nasdaq, and satisfaction or waiver, as applicable, of other customary closing conditions in the Business Combination Agreement.

About the Business Combination

On April 22, 2025, VERAXA entered into the Business Combination Agreement, as amended. Upon closing of the Business Combination, the combined company will become a publicly traded company listed on Nasdaq trading under the symbol "VRXA".